News

Targeted Oncology1h
Lifileucel Offers Promising Long-Term Efficacy in Advanced Melanoma
During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in ...
Targeted Oncology2h
Oncologists Weigh Pros and Cons of Dual Oral Therapy in CLL
During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...
Targeted Oncology5h
Durable Efficacy of Intravesical Mitomycin Confirmed in Phase 3 Trial for NMIBC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology6h
Onvansertib Shows Promising Early Efficacy in First-Line KRAS-Mutated mCRC
Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, ...
Targeted Oncology7h
Immunosuppressive Antibody Discontinued After Patient Death in Lymphoma Trial
Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting ...
Targeted Oncology8h
FDA Grants Priority Review for Liso-Cel in Marginal Zone Lymphoma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology10h
Current Evidence and Future Directions
An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and ...